Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
Pacira BioSciences, Inc. is a U.S.-based biopharmaceutical company focused on developing, manufacturing, and commercializing non-opioid pain management and regenerative health solutions. The company operates primarily within the pharmaceuticals and medical therapeutics industries, with an emphasis on addressing post-surgical pain and musculoskeletal conditions. Pacira’s business model centers on proprietary drug delivery technologies designed to provide long-acting therapeutic benefits while reducing reliance on opioids.
The company’s primary revenue drivers are its branded pharmaceutical products, most notably EXPAREL, a long-acting local anesthetic, and IOVERA°, a cryoanalgesia-based pain management treatment. Pacira serves hospitals, ambulatory surgical centers, orthopedic practices, and other healthcare providers, primarily in the United States. Founded in 2006, the company evolved from a development-stage biotechnology firm into a commercial-stage organization following the U.S. regulatory approval and commercialization of EXPAREL, which established its position in the non-opioid pain management market.
Business Operations
Pacira conducts its operations through a single integrated reporting structure focused on non-opioid pain management and regenerative health solutions, though its activities are commercially organized around distinct product platforms. EXPAREL represents the core pharmaceutical business, generating the majority of company revenue through perioperative use across multiple surgical specialties. IOVERA° contributes additional revenue through device-based cryoanalgesia treatments for both surgical and non-surgical pain indications.
The company controls proprietary liposomal drug delivery technology and cryotherapy technology used in its products, along with in-house and contracted manufacturing capabilities. Pacira operates primarily in the domestic U.S. market, with limited international sales and distribution. Its wholly owned subsidiary MyoScience, Inc. supports the commercialization and development of the IOVERA° platform. The company also maintains collaborations with medical institutions and healthcare providers to expand clinical adoption and label indications.
Strategic Position & Investments
Pacira’s strategic direction is centered on expanding the clinical utility and market penetration of its non-opioid pain management portfolio. Growth initiatives include label expansions for EXPAREL, increased adoption across additional surgical procedures, and continued investment in education and commercialization efforts targeting healthcare systems focused on opioid reduction. The company also emphasizes lifecycle management and formulation innovation to extend product relevance.
Strategically, Pacira has pursued acquisitions and internal development to broaden its technology base. The acquisition of MyoScience, Inc. strengthened its position in device-based pain management, while ongoing investment in regenerative health research reflects an effort to diversify beyond traditional anesthetics. Pacira has also explored emerging therapeutic areas related to musculoskeletal health, though some development programs have faced regulatory or clinical uncertainty, which the company has publicly acknowledged.
Geographic Footprint
Pacira BioSciences is headquartered in Parsippany, New Jersey, with its primary commercial focus in North America, particularly the United States. The majority of its revenue is generated domestically, reflecting strong penetration in U.S. hospitals and surgical centers. Manufacturing and research activities are also largely U.S.-based, supporting regulatory compliance and supply chain control.
Internationally, Pacira maintains a limited presence through distribution partnerships and selective market entry strategies in Europe and other regions. While global expansion is not currently the company’s primary growth driver, international markets represent a potential long-term opportunity for its non-opioid pain management technologies, subject to regulatory approvals and reimbursement frameworks.
Leadership & Governance
Pacira is led by an experienced executive team with backgrounds in pharmaceuticals, medical devices, and healthcare commercialization. The leadership emphasizes disciplined capital allocation, evidence-based medicine, and addressing unmet clinical needs related to pain management and opioid reduction. The company operates under a governance framework aligned with U.S. public company standards and regulatory oversight.
Key executives include:
- Frank D. Lee – President and Chief Executive Officer
- Sterling L. Bates – Chief Financial Officer
- Jeffrey B. Ludwin – Chief Operating Officer
- Jules Haimovitz – Chief Medical Officer
- Craig J. Slauterbeck – Chief Commercial Officer
The leadership team’s strategic vision focuses on sustaining market leadership in non-opioid pain management while selectively expanding into adjacent therapeutic areas that align with the company’s core technologies and clinical expertise.